Australian company Minomic has developed the MiCheck Prostate blood test that uses an algorithm, together with other biomarkers, to estimate the risk of a patient having aggressive prostate cancer. The diagnostic overcomes the low accuracy of conventional screening tests to reduce unnecessary intervention such as painful biopsies and improve overall management of the patient. 

The test was launched in the US in 2022, after Minomic was the first to sign up to the 20/20 GeneSystems’ Clinical Lab Innovation Axcellerator (CLIAx) - providing a ‘soft landing’ to help diagnostic test innovators worldwide to substantially reduce the time and cost of launching their tests in the U.S. 

Minomic CEO and Managing Director Dr Brad Walsh joins MTPConnect host Caroline Duell from Sydney to talk about the company’s commercialisation journey and how it launched into the US market after working with urologists around the world during COVID-19. Minomic received funding through Federal Government’s Modern Manufacturing Initiative and is working with Sonic Healthcare to make the test available in Australia.